Depression & Anxiety Disorders: 2018 Drug Development Pipeline Review – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Depression
and Anxiety Disorders Drug Development Pipeline Review, 2018”

report has been added to ResearchAndMarkets.com’s offering.

This report provides an overview of the pipeline landscape for
depression and anxiety disorders. It provides comprehensive information
on the therapeutics under development and key players involved in
therapeutic development for post-traumatic stress disorder (PTSD),
obsessive-compulsive disorder (OCD) and depression, and features dormant
and discontinued products.

  • PTSD: There are 38 products in development for this indication.
  • OCD: There are 9 products in development for this indication.
  • Depression: There are 212 products in development for this indication.

Molecular targets acted on by products in development for depression and
anxiety disorders include neurotransmitter receptors such as glutamate
receptors and 5-hydroxytryptamine receptors. Companies operating in this
pipeline space include NeuroRx, Amorsa Therapeutics and Johnson
Johnson.

Scope

  • Which companies are the most active within each pipeline?
  • Which pharmaceutical approaches are the most prominent at each stage
    of the pipeline and within each indication?
  • To what extent do universities and institutions play a role within
    this pipeline, compared to pharmaceutical companies?
  • What are the most important RD milestones and data publications to
    have happened in this disease area?

Key Topics Covered

1 Table of Contents

2 Introduction

2.1 Depression and Anxiety Disorders Report Coverage

2.2 Post-Traumatic Stress Disorder (PTSD) – Overview

2.3 Obsessive-Compulsive Disorder – Overview

2.4 Depression – Overview

3 Therapeutics Development

3.1 Post-Traumatic Stress Disorder (PTSD)

3.2 Obsessive-Compulsive Disorder

3.3 Depression

4 Therapeutics Assessment

4.1 Post-Traumatic Stress Disorder (PTSD)

4.2 Obsessive-Compulsive Disorder

4.3 Depression

5 Companies Involved in Therapeutics Development

5.1 Post-Traumatic Stress Disorder (PTSD)

5.2 Obsessive-Compulsive Disorder

5.3 Depression

6 Dormant Projects

6.1 Post-Traumatic Stress Disorder (PTSD)

6.2 Obsessive-Compulsive Disorder

6.3 Depression

7 Discontinued Products

7.1 Post-Traumatic Stress Disorder (PTSD)

7.2 Obsessive-Compulsive Disorder

7.3 Depression

8 Product Development Milestones

8.1 Post-Traumatic Stress Disorder (PTSD)

8.2 Obsessive-Compulsive Disorder

8.3 Depression

Companies Featured

  • Acadia Pharmaceuticals Inc
  • Ache Laboratorios Farmaceuticos SA
  • Actinogen Medical Ltd
  • Adamed Sp. z o.o
  • Addex Therapeutics Ltd
  • Bionomics Ltd
  • BioXcel Therapeutics Inc
  • Clera Inc
  • Corcept Therapeutics Inc
  • Delpor Inc
  • DURECT Corp
  • Eisai Co Ltd
  • Eli Lilly and Co
  • Embera NeuroTherapeutics Inc
  • FPRT Bio Inc
  • GlaxoSmithKline Plc
  • GliaCure Inc
  • H. Lundbeck AS
  • Kissei Pharmaceutical Co Ltd
  • Lead Discovery Center GmbH
  • Les Laboratoires Servier SAS
  • Lixte Biotechnology Holdings Inc
  • Luye Pharma Group Ltd
  • Mapi Pharma Ltd
  • Medlab Clinical Ltd
  • Meta-IQ ApS
  • Mitsubishi Tanabe Pharma Corp
  • Navitor Pharmaceuticals Inc
  • Neuralstem Inc
  • Neurocrine Biosciences Inc
  • Sumitomo Chemical Co Ltd
  • Takeda Pharmaceutical Co Ltd
  • Trevena Inc
  • VistaGen Therapeutics Inc
  • and many more…

For more information about this report visit https://www.researchandmarkets.com/research/w5czfd/depression_and?w=4